Coronavirus Update: Japan Approves Antibody Cocktail In Short Order
Plus, India Emerges Among Top Vaccine Buyers
Executive Summary
Japan has granted an emergency approval to Chugai/Roche/Regeneron's antibody cocktail after a rapid review, while India has emerged as one of the top purchasers globally of COVID-19 vaccines as it looks to protect more of its population.
You may also be interested in...
Coronavirus Update: More Approval, Trial Progress For Non-Vaccine Options
Multiple non-vaccine options for COVID-19 continue to progress, with promising new clinical results for Sorrento's small molecule drug and a supplementary approval in Japan for Chugai's antibody combo. Meanwhile, China's CRDC has in-licensed technology for Ligand to apply to an oral antiviral it is developing. Meanwhile, SK Biosciences' novel nanoparticle vaccine is positive in early trials.
Coronavirus Update: Brii Files US EUA For Antibody Combo
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
Coronavirus Update: Japan Approves Sotrovimab
Japan approves a second antibody therapy for COVID-19 in short order, while India gives the go-ahead to a local clinical program for Novavax/Serum Institute's recombinant protein vaccine candidate.